A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia

← catalyst calendar

NCT07619118 · readout in 282 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 3

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

200estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-09-15

estimated

When the study began enrolling

Primary completion

2027-05-28

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-05-28

estimated

The whole study's end, after follow-up

First posted

2026-06-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-06-01

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Hypercholesterolaemia

Interventions

Combination product: laroprovstat/rosuvastatin 1
Combination product: laroprovstat/rosuvastatin 2
Combination product: laroprovstat/rosuvastatin 3
Combination product: laroprovstat/rosuvastatin 4
Drug: Placebo to match laroprovstat/rosuvastatin 1,2,3
Drug: Placebo to match laroprovstat/rosuvastatin 4
Drug: Rosuvastatin 1
Drug: Rosuvastatin 2
Drug: Rosuvastatin 3
Drug: Rosuvastatin 4
Drug: Placebo to match Rosuvastatin

Primary outcome

what the primary-completion date above is the date OF

Relative change in LDL-C at 8 weeks

measured 8 weeks

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed